S

Scilex Holding Co
NASDAQ:SCLX

Watchlist Manager
Scilex Holding Co
NASDAQ:SCLX
Watchlist
Price: 14.35 USD -1.78% Market Closed
Market Cap: 108.9m USD

Operating Margin
Scilex Holding Co

-225.6%
Current
-143%
Average
6%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-225.6%
=
Operating Profit
-105.4m
/
Revenue
46.7m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Scilex Holding Co
NASDAQ:SCLX
108.9m USD
-226%
US
Eli Lilly and Co
NYSE:LLY
1T USD
44%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
496.6B USD
27%
CH
Roche Holding AG
SIX:ROG
256.7B CHF
34%
UK
AstraZeneca PLC
LSE:AZN
210.7B GBP
24%
CH
Novartis AG
SIX:NOVN
208.2B CHF
33%
US
Merck & Co Inc
NYSE:MRK
251.4B USD
38%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
42%
IE
Endo International PLC
LSE:0Y5F
209B USD
11%
US
Pfizer Inc
NYSE:PFE
143.2B USD
29%
No Stocks Found

Scilex Holding Co
Glance View

Market Cap
108.9m USD
Industry
Pharmaceuticals

Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. The company is headquartered in Palo Alto, California and currently employs 2 full-time employees. The company went IPO on 2021-01-11. The firm's commercial product, ZTlido (lidocaine topical system) 1.8%, or ZTlido, is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. The company also commercializes Gloperba (colchicine USP) oral solution, a prophylactic treatment for painful gout flares in adults. The firm's three product candidates are SP-102 or SEMDEXA, a Phase 3, viscous gel formulation of a used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica; SP-103 5.4%, a Phase 2, triple-strength formulation of ZTlido, for the treatment of low back pain; and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule, for the treatment of chronic pain, fibromyalgia in multiple Phase 1 program.

SCLX Intrinsic Value
Not Available
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-225.6%
=
Operating Profit
-105.4m
/
Revenue
46.7m
What is the Operating Margin of Scilex Holding Co?

Based on Scilex Holding Co's most recent financial statements, the company has Operating Margin of -225.6%.

Back to Top